Regina Graul
CEO, President & Director
Good morning, everyone, and thank you for joining us today. I am Regina Graul, Chief Executive Officer of Cyclerion Therapeutics. I’m joined today by Dr. Husseini Manji, a globally recognized leader in neuroscience and mental health innovation. Dr. Manji’s distinguished career spans leadership roles at the National Institute of Health, where he advanced foundational research on synaptic plasticity and at Janssen, Johnson & Johnson, where he served as Global Head of Neuroscience, driving the development of novel treatments for mood disorders. He currently holds professorships at both Oxford University and Yale University, focusing on severe neuropsychiatric disorders and as a member of the National Academy of Medicine.
Dr. Manji also played a key leadership role in translating the scientific discovery of esketamine’s potential into SPRAVATO, the FDA-approved treatment for treatment-resistant depression. Dr. Manji is widely regarded as a thought leader in mental health policy and innovation with hundreds of peer-reviewed publications and a track record of translating science into transformative therapies. Dr. Manji is an adviser to Cyclerion and has been instrumental in informing the strategy for our lead program, CYC-126.
We’re excited to share how we are pioneering a new therapeutic category in neuropsychiatry, one that leverages precision anesthesia, advanced EEG-guided technology and deep clinical precedence to address the enormous unmet need in treatment-resistant depression. Before we get started, I would like to remind everyone that certain matters discussed in this presentation are forward-looking statements.
We may, in some cases, use terms such as potential, may, expects, plans, could, opportunity, intends or other words that convey uncertainty
Read the full article here
